Albumin-Bound Paclitaxel


Albumin-Bound Paclitaxel, Protein-Bound Paclitaxel, Abraxane

  • Indications
  1. FDA Approved (part of combination protocols)
    1. Non-Small Cell Lung Cancer (non-operative, not amenable to Radiation Therapy)
    2. Pancreatic Cancer (metastatic)
    3. Breast Cancer (metastatic, refractory or relapsing)
  2. Off-Label
    1. Metastatic Melanoma
    2. Ovarian Cancer or associated cancers (fallopian tube cancer, primary peritoneal cancer)
  • Contraindications
  1. Hepatic Impairment (relative contraindication)
    1. Increased toxicity risk
  • Mechanism
  1. See Mitotic Inhibitor Chemotherapy
  2. Albumin-Bound Paclitaxel is a injection formulation of nanoparticles
    1. Removes toxicity inducing solvents, improving Paclitaxel safety and Therapeutic Index
  3. Paclitaxel is a taxane Antineoplastic Agent
    1. Derived from extract of the Pacific yew tree (Taxus brevifolia)
  4. Paclitaxel has antineoplastic activity as a an antitubulin agent
    1. Binds and stabilizes tubulin
    2. Inhibits microtubule disassembly
    3. Results in cell cycle arrest in G2/M phase
  5. Paclitaxel induces apoptosis
    1. Binds and blocks apoptosis inhibitor Protein Bcl-2 (B-cell Leukemia 2)
  • Medications
  1. Protein-Bound Paclitaxel for IV Infusion: 100 mg Vial
  • Dosing
  1. See other references for disease specific dosing protocols
  • Adverse Effects
  1. Hypersensitivity Reaction
  2. Myelosuppression (Bone Marrow suppression) with Neutropenia
  3. Peripheral Neuropathy (sensory)
  4. Future impaired fertility
  5. Alopecia
  6. Cardiac conduction abnormalities
  • Safety
  1. Avoid in Lactation
  2. Avoid in pregnancy (all trimesters)
    1. Use reliable Contraception
  3. Monitoring
    1. Complete Blood Count